AmerisourceBergen Names Keri Mattox as Vice President, Corporate and Investor Relations
AmerisourceBergen Corporation (NYSE: ABC) today announced that Keri Mattox will join the Company as Vice President, Corporate
& Investor Relations, effective January 3, 2017. In this role, Ms. Mattox will assume responsibility for the Company’s
relationships with the analyst and investor community, reporting directly to Tim G. Guttman, Executive Vice President and Chief
Financial Officer.
Ms. Mattox succeeds Barbara A. Brungess, currently Vice President, Corporate & Investor Relations, who has announced that
she is leaving the Company, effective December 31, 2016, to pursue other opportunities.
“I am delighted to have Keri lead our investor relations efforts going forward. In addition to the investor relations and
healthcare industry experience she brings to AmerisourceBergen, Keri has established a great reputation and many strong
relationships across the financial community,” said Steven H. Collis, Chairman, President and Chief Executive Officer of
AmerisourceBergen. “We look forward to Keri’s contributions and support as AmerisourceBergen continues to pursue its long-term
growth strategies in the global pharmaceutical supply chain.”
“I also want to thank Barbara for her leadership and dedication to AmerisourceBergen during the 16 years she has been with the
Company,” Collis continued. “Barbara has made a significant impact on AmerisourceBergen during her tenure and helped us build and
solidify relationships with the investment community. Her integrity, sound judgment and industry expertise have served
AmerisourceBergen and our shareholders extremely well. It has been a pleasure working with Barbara, and we wish her all the
best.”
Ms. Mattox brings over 15 years of investor relations and corporate communications experience spanning both corporate roles and
public relations firms. She has significant experience within the specialty, generics and biotech pharmaceutical sectors. Most
recently, Ms. Mattox served as Senior Vice President, Investor Relations & Corporate Public Affairs with Endo International, a
role she assumed in 2015 following Endo’s acquisition of Auxilium Pharmaceuticals, where she led the investor relations function.
At Endo, she was responsible for investor relations, corporate communications and government affairs. Ms. Mattox started her career
in journalism with positions at the Washington Post and Hearst Newspapers before transitioning into public relations and
then the pharmaceutical industry.
Ms. Mattox graduated magna cum laude with a bachelor’s degree in Political Science from Boston University and has her master’s
degree in Journalism from the University of Maryland.
As of January 3, 2017, Ms. Mattox can be reached at AmerisourceBergen at 610-576-7801 and kmattox@amerisourcebergen.com.
In the interim period, Investor Relations questions can be directed to Bennett Murphy, Manager, Corporate & Investor
Relations at 610-727-3693 and bmurphy@amerisourcebergen.com.
About AmerisourceBergen
AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both
healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With
services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services,
AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human and animal health.
With over $145 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 19,000
people. AmerisourceBergen is ranked #12 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook,"
"forecast," "would," "could," "should," "can," "will," "project," "intend," "plan," "continue," "sustain," "synergy," "on track,"
"believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are
intended to identify such forward-looking statements. These statements are based on management's current expectations and are
subject to uncertainty and change in circumstances. These statements are not guarantees of future performance and are based on
assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors
that could cause actual results to differ materially from those projected, anticipated, or implied are the following: competition;
industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and
services; changes in pharmaceutical market growth rates; unfavorable trends in brand and generic pharmaceutical pricing, including
in rate or frequency of price inflation or deflation; substantial defaults in payment, material reduction in purchases by or the
loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier mix; the retention of key customer or
supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or
suppliers; changes to customer or supplier payment terms; the disruption of AmerisourceBergen's cash flow and ability to return
value to its stockholders in accordance with its past practices; risks associated with the strategic, long-term relationship
between Walgreens Boots Alliance, Inc. and AmerisourceBergen, including with respect to the pharmaceutical distribution agreement
and/or the global sourcing arrangement; changes in the United States healthcare and regulatory environment, including changes that
could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the
pharmaceutical supply channel and pharmaceutical compounding; federal and state government enforcement initiatives to detect and
prevent suspicious orders of controlled substances and the diversion of controlled substances; federal and state prosecution of
alleged violations of related laws and regulations, and any related litigation, including shareholder derivative lawsuits or other
disputes relating to our distribution of controlled substances; increased federal scrutiny and qui tam litigation for alleged
violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale, purchase
and/or dispensing of pharmaceutical products or services and any related litigation; material adverse resolution of pending legal
proceedings; declining reimbursement rates for pharmaceuticals; the acquisition of businesses that do not perform as expected, or
that are difficult to integrate or control, including the integration of PharMEDium, or the inability to capture all of the
anticipated synergies related thereto; regulatory action in connection with the production, labeling or packaging of products
compounded by our compounded sterile preparations (CSP) business; declining economic conditions in the United States and abroad;
financial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; interest rate and foreign
currency exchange rate fluctuations; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices
Act, anti-bribery laws and economic sanctions and import laws and regulations; malfunction, failure or breach of sophisticated
information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer
of personal data; changes in tax laws or legislative initiatives that could adversely affect AmerisourceBergen's tax positions
and/or AmerisourceBergen's tax liabilities or adverse resolution of challenges to AmerisourceBergen's tax positions; natural
disasters or other unexpected events that affect AmerisourceBergen's operations; the impairment of goodwill or other intangible
assets, resulting in a charge to earnings; and other economic, business, competitive, legal, tax, regulatory and/or operational
factors affecting AmerisourceBergen's business generally. Certain additional factors that management believes could cause actual
outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk
Factors) in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016 and elsewhere in that report and
(ii) in other reports filed by the Company pursuant to the Securities Exchange Act.
AmerisourceBergen Corporation
Tim Guttman, 610-727-7000
View source version on businesswire.com: http://www.businesswire.com/news/home/20161219005195/en/